Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Surrozen, Inc.NASDAQ: SRZN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$127.44M, compared with -$26.68M a year earlier. Trailing-twelve-month EBITDA was -$342.25M.

Context

  • EBITDA amounted to 6945.3% of revenue in FY2025, up 6362.3 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$117.25M (+51.4%) for the fiscal year ending Dec 2026, a step up from the -288.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$127.44M+30.4% QoQ
Last fiscal yearDec 2025
-$241.49M-288.7% YoY
LTMMar 2026
-$342.25M-325.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-377.7%-137.9%+239.8 pp
1 year-288.7%+51.4%+340.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(241.49M) USD
Year-over-year change
-288.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 EBITDA of -$342.25M is the lowest of the 8 companies compared; the peer median is -$34.56M.
  • Its year-over-year change of -325.9% is the lowest of 8, against a peer median of +18.9%.
  • EBITDA amounts to 4567.0% of revenue for SRZN, versus a peer median of 427.9%.
SRZN Competitors Peer median
EBITDA for SRZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$127.04M +256.7%—102.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.31M +41.5%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026-$21.76M -35.5%——
IMMXImmix Biopharma, Inc.LTM Mar 2026-$34.56M -66.8%——
TILInstil Bio, Inc.LTM Mar 2026-$41.59M +38.3%——
SEERSeer, Inc.LTM Mar 2026-$64.35M +18.9%—427.9%
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M -226.0%—874.0%
SRZNSurrozen, Inc.LTM Mar 2026-$342.25M -325.9%—4567.0%
Peer median (excluding SRZN) -$34.56M+18.9%—427.9%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.5M010.66M3.48M
Cost of Revenue3.3M3.27M27.23M0537K
Gross Profit(3.3M)9.23M(27.23M)10.66M2.94M
Gross Margin—73.8%—100.0%84.6%
Research & Development36.88M37.01M27.23M21.13M29.37M
Selling, General & Admin14.21M19.83M15.8M15.06M16.2M
Operating Expenses51.09M53.57M18.55M36.19M45.03M
Depreciation & Amortization3.3M1.96M1.91M1.44M537K
EBITDA(51.35M)(34.05M)(41.13M)(62.12M)(241.49M)
EBITDA Margin—-272.4%—-583.0%-6945.3%
Operating Income(54.39M)(44.34M)(45.78M)(25.54M)(42.09M)
Operating Margin—-354.7%—-239.7%-1210.6%
Interest Income72K781K2.34M1.69M3.02M
Interest Expense00000
Other Income / Expenses(257K)8.34M2.74M(38.03M)(199.93M)
Income Before Tax(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Pre-Tax Margin—-288.0%—-596.6%-6960.8%
Income Tax Expense00000
Net Income(52.51M)(36M)(43.04M)(63.56M)(242.03M)
Net Margin—-288.0%—-596.6%-6960.8%
EPS (Basic)(23.40)(15.55)(21.33)(21.67)(32.37)
EPS (Diluted)(23.40)(15.55)(21.33)(21.67)(32.37)
Weighted Avg Shares2.34M2.31M2.02M2.93M7.48M
Weighted Avg Shares (Diluted)2.34M2.31M2.02M2.93M7.48M

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.